.Pharmacolibrary.Drugs.ATC.L.L01FX28 .Pharmacolibrary.Drugs.ATC.L.L01FX28| name: | Glofitamab |
| ATC code: | L01FX28 | route: | intravenous |
| n-compartments | 2 |
Glofitamab is a humanized, bispecific CD20-directed CD3 T-cell engager antibody used for the treatment of B-cell non-Hodgkin’s lymphoma. It induces T-cell mediated cytotoxicity of malignant B cells. Glofitamab was approved by the FDA in 2023 under the trade name Columvi.
Pharmacokinetic parameters in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma following intravenous administration.